GRI Bio Inc. - Asset Resilience Ratio
GRI Bio Inc. (GRI) has an Asset Resilience Ratio of 21.84% as of June 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GRI working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (None–None)
This chart shows how GRI Bio Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see GRI Bio Inc. asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down GRI Bio Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read GRI Bio Inc. total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.75 Million | 21.84% |
| Total Liquid Assets | $1.75 Million | 21.84% |
Asset Resilience Insights
- Good Liquidity Position: GRI Bio Inc. maintains a healthy 21.84% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
GRI Bio Inc. Industry Peers by Asset Resilience Ratio
Compare GRI Bio Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Vaxcyte Inc
NASDAQ:PCVX |
Biotechnology | 41.54% |
|
Enliven Therapeutics Inc.
NASDAQ:ELVN |
Biotechnology | 83.46% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.12% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
Annual Asset Resilience Ratio for GRI Bio Inc. (None–None)
The table below shows the annual Asset Resilience Ratio data for GRI Bio Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About GRI Bio Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung … Read more